PD-1 drugs for Esophageal Squamous Cell Carcinoma
4 tracked PD-1 drugs in the Esophageal Squamous Cell Carcinoma race. The class explanation lives on the PD-1 page; the full indication pipeline across every mechanism is on the Esophageal Squamous Cell Carcinoma page.
4 approved / phase 4
Head-to-head evidence: Nivolumab vs Pembrolizumab · Nivolumab vs Tislelizumab · Opdivo Qvantig vs Pembrolizumab · Opdivo Qvantig vs Tislelizumab · Pembrolizumab vs Tislelizumab